CA3168783A1 - Cpg-adjuvanted sars-cov-2 virus vaccine - Google Patents

Cpg-adjuvanted sars-cov-2 virus vaccine Download PDF

Info

Publication number
CA3168783A1
CA3168783A1 CA3168783A CA3168783A CA3168783A1 CA 3168783 A1 CA3168783 A1 CA 3168783A1 CA 3168783 A CA3168783 A CA 3168783A CA 3168783 A CA3168783 A CA 3168783A CA 3168783 A1 CA3168783 A1 CA 3168783A1
Authority
CA
Canada
Prior art keywords
cov
sars
vaccine
inactivated
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168783A
Other languages
English (en)
French (fr)
Inventor
Andreas Meinke
Michael Mohlen
Christoph Reinisch
Robert Schlegl
Christian TAUCHER
John D. Campbell
David NOVACK
Robert S. Janssen
Jurgen Heindl-Wruss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Dynavax Technologies Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Application filed by Individual filed Critical Individual
Priority claimed from PCT/IB2021/052858 external-priority patent/WO2021176434A1/en
Publication of CA3168783A1 publication Critical patent/CA3168783A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3168783A 2020-04-06 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine Pending CA3168783A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20168324.0 2020-04-06
EP20202124.2 2020-10-15
EP20202124 2020-10-15
EP20211936.8 2020-12-04
EP20211936 2020-12-04
EP21154645 2021-02-01
EP21154645.2 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
USPCT/US2021/020313 2021-03-01
EP21160933 2021-03-05
EP21160933.4 2021-03-05
PCT/IB2021/052858 WO2021176434A1 (en) 2020-03-01 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine

Publications (1)

Publication Number Publication Date
CA3168783A1 true CA3168783A1 (en) 2021-09-10

Family

ID=83887208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168783A Pending CA3168783A1 (en) 2020-04-06 2021-04-06 Cpg-adjuvanted sars-cov-2 virus vaccine

Country Status (4)

Country Link
KR (1) KR20230005814A (ko)
CN (1) CN115666633A (ko)
CA (1) CA3168783A1 (ko)
MX (1) MX2022010781A (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131356A3 (zh) * 2022-01-07 2023-08-24 广东粤港澳大湾区国家纳米科技创新研究院 四氧化三锰颗粒在制备疫苗佐剂中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116983401A (zh) * 2023-06-29 2023-11-03 贝湾生物科技有限公司 基于sars1病毒的新冠加强免疫疫苗

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131356A3 (zh) * 2022-01-07 2023-08-24 广东粤港澳大湾区国家纳米科技创新研究院 四氧化三锰颗粒在制备疫苗佐剂中的应用

Also Published As

Publication number Publication date
KR20230005814A (ko) 2023-01-10
CN115666633A (zh) 2023-01-31
MX2022010781A (es) 2023-03-09

Similar Documents

Publication Publication Date Title
AU2021229710A1 (en) CPG-adjuvanted SARS-CoV-2 virus vaccine
EP3393509B1 (en) Virus purification
WO2021204825A2 (en) INACTIVATED SARS-CoV-2 VIRUS VACCINE
CA3168783A1 (en) Cpg-adjuvanted sars-cov-2 virus vaccine
JP2022538693A (ja) タンパク質加水分解標的ウイルス、その生ワクチン及びその作製方法と用途
WO2021150874A1 (en) Recombinant influenza viruses with stabilized na
CA3170422A1 (en) Coronavirus disease (covid-19) vaccine
WO2021222228A1 (en) A live attenuated measles virus vectored vaccine for sars-cov-2
CN117098551A (zh) 编码截短的ns1蛋白和sars-cov受体结合域的流感病毒
WO2019084310A1 (en) HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
WO2021041624A2 (en) Recombinant influenza viruses with stabilized ha for replication in eggs
CA2826234A1 (en) Novel vaccines against the a/h1n1 pandemic flu virus
WO2020081937A1 (en) Methods and compositions for treating negative-sense single-stranded rna virus
EP3895729A1 (en) Cpg-adjuvanted sars-cov-2 virus vaccine
CA3168784A1 (en) Inactivated sars-cov-2 virus vaccine
US20230285544A1 (en) Synthetic defective interfering coronaviruses
AU2021250704A1 (en) Influenza vaccines
WO2023148256A1 (en) Inactivated sars-cov-2 virus vaccine
CN107151659B (zh) 一种流感病毒株及其应用
WO2023250055A1 (en) Immunogenic compositions for herpes simplex virus proteins
WO2021173965A1 (en) Identification of variable influenza residues and uses thereof
CA3234653A1 (en) Influenza vaccines
CN117693359A (zh) 作为免疫原的广泛反应性病毒抗原、其组合物和使用方法
WO2022090484A2 (en) Viral vector